United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

19 Oct 2017
Change (% chg)

$-0.53 (-1.04%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Anstice, David 

Mr. David W. Anstice is Independent Director of Alkermes Plc. From 2006 until his retirement in 2008, Mr. Anstice served as Executive Vice President of Merck, with responsibility for enterprise strategy and implementation. During two separate parts of this period he was acting President, Global Human Health and President of Merck’s business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Merck’s Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions including President, U.S. Human Health; President, Human Health, the Americas; President, U.S./Canada; and President, Human Health, Europe. He reported to the Merck CEO from 1994 until his retirement in 2008. Mr. Anstice is currently a director of CSL Limited, a global specialty biopharmaceutical company and a director of the private company NeuClone Pharmaceuticals Pty Ltd., a cell line production company. Mr. Anstice is also Chairman and President of the board for the University of Sydney USA Foundation, Vice Chairman and a member of the board of the U.S. Studies Centre at the University of Sydney, Australia, a member of the U.S. Advisory Council of the American Australian Association in New York, and an Adjunct Professor at the University of Sydney Business School.

Basic Compensation

Total Annual Compensation, USD 96,500
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 423,986
Fiscal Year Total, USD 520,486

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops


Shane Cooke


James Frates


Kathryn Biberstein


Elliot Ehrich


Iain Brown

As Of  30 Dec 2016